Organotin(IV) compounds have wide applications in industrial and agricultural fields owing to their ability to act as poly(vinyl chloride) stabilizers and catalytic agents as well as their medicinal properties. Moreover, organotin(IV) compounds may have applications as antitumor, anti-inflammatory, antifungal, or antimicrobial agents based on the observation of synergistic effects following the binding of their respective ligands, resulting in the enhancement of their biological activities. In this review, we describe the antiproliferative activities of organotin(IV) compounds in various human cancer cell lines based on different types of ligands. We also discuss the molecular mechanisms through which organotin(IV) compounds induce cell death via apoptosis through the mitochondrial intrinsic pathway. Finally, we present the mechanisms of cell cycle arrest induced by organotin(IV) compounds. Our report provides a basis for studies of the antitumor activities of organotin(IV) compounds and highlights the potential applications of these compounds as anticancer metallodrugs with low toxicity and few side effects.
Chemotherapy and radiotherapy are often used to treat Acute Lymphoblastic Leukemia (ALL). However, the resistance problem of treatment using the current drug in ALL patients has decreased the effectiveness of such therapy. Therefore, a study needs to be conducted to identify the potential of new anticancer agents. Organotin (IV) dithiocarbamate, an organometallic compound, causes toxic effects on cancer cells in vitro and in vivo. This study examines the cytotoxic effects and mode of cell death of novel organotin (IV) dithiocarbamate compounds of triphenyltin (IV) diisopropyldithiocarbamate (compound 1), triphenyltin (IV) diallyldithiocarbamate (compound 2) and triphenyltin (IV) diethyldithiocarbamate (compound 3) on the acute lymphoblastic leukemia cell line, CCRF CEM (CCL-119). An MTT assay was used for the determination of the cytotoxicity of the compounds by treating cells with compounds 1-3 at the highest concentration of 10 µm for 24 h. The induction of the mode of cell death for compounds 1, 2, and 3 were identified using Annexin V-FITC/PI assay. From the results, all triphenyltin (IV) dithiocarbamate compounds have substantial cytotoxic effects with IC50 values between 0.18-0.20 μm. The chemicals induced apoptosis cell death in CCL-119 cells, based on the determination of cell death mode. However, statistical analysis showed that only apoptotic cell death for treatment with compounds 1-2 is significant compared to negative controls. In conclusion, all these compounds have a high cytotoxicity effect and are able to cause cell death via apoptosis in CCL-119 cells.
Imatinib mesylate (IM), a leading treatment for chronic myeloid leukaemia (CML), has sparked worries about the possibility of CML patients developing a resistance to it. As a result, researchers are becoming more interested in organotin(IV) compounds due to their strong potential to be developed as anticancer agents and employed as an option to address the issues regarding IM-resistance therapy. Generally, this study is to determine the cytotoxicity induced by diorganotin(IV) dithiocarbamate compounds in K562 human erythroleukaemia cells. The two novel diorganotin(IV) compounds namely diphenyltin(IV) N-methyl-N-phenethyldithiocarbamate (C1) and dibutyltin(IV) N-methyl-N-phenethyldithiocarbamate (C2) were assessed their cytotoxicity via MTT [3-(4-5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay and mode of cell death via Annexin V-FITC/PI assay with the duration treatment of 24 h. Both compounds displayed strong cytotoxicity in K562 cells. At concentration of 4.2 µM for C1 and 1.6 µM for C2, both compounds were able to induce 49.70% and 46.83% apoptotic events, respectively. The changes in cells' morphological can also be seen 24 h after being exposed to the compounds at their respective IC50 doses. The findings demonstrated that the morphology of the cells was similar to apoptotic features, including cell shrinkage and the production of apoptotic bodies, meanwhile, the low levels of necrotic cells (<1%) also can be seen via cell lysis. In conclusion, both compounds possess the potential as antileukaemia drugs nevertheless, further studies on their action mechanism are required to ratify their qualities and suitability in the research of anticancer drugs development.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.